Trenbolone hexahydrobenzylcarbonate, or trenbolone cyclohexylmethylcarbonate, sold under the brand names Parabolan and Hexabolan, is a synthetic, injected anabolic–androgenic steroid (AAS) of the nandrolone group and an androgen ester – specifically, the C17β hexahydrobenzylcarbonate (cyclohexylmethylcarbonate) ester of trenbolone – which was marketed in France for medical use in humans but has since been discontinued.
|Trade names||Parabolan, Hexabolan|
|Other names||Trenbolone cyclohexylmethylcarbonate; Estra-4,9,11-trien-17β-ol-3-one 17β-cyclohexylmethylcarbonate|
|Drug class||Androgen; Anabolic steroid; Androgen ester; Progestogen|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||410.554 g·mol−1|
|3D model (JSmol)|
It was introduced in France in 1980 and was voluntarily discontinued by its manufacturer in 1997. The drug acts as a long-lasting prodrug of trenbolone when administered via intramuscular injection. It was used clinically at a dosage of one ampoule (76 mg, corresponding to 50 mg trenbolone base) every 10 days.
- Yarrow JF, McCoy SC, Borst SE (2010). "Tissue selectivity and potential clinical applications of trenbolone (17beta-hydroxyestra-4,9,11-trien-3-one): A potent anabolic steroid with reduced androgenic and estrogenic activity". Steroids. 75 (6): 377–89. doi:10.1016/j.steroids.2010.01.019. PMID 20138077. S2CID 205253265.